Archives

BioStock published an article on 12 July 2021 about Aptahem, which can be read in full below. During 2021, sepsis company Aptahem has taken several steps to prepare for its first clinical [...]

Aptahem AB (publ) announces today that the company has received information that the European Patent Office (EPO) has issued an Intention to Grant of the EU patent application EP 18783424.7 [...]

BioStock published an article on 1 July 2021 about Aptahem, which can be read in full below. Since 2019, Aptahem has collaborated with the Cardiovascular Research Centre (CVRC) at Örebro [...]

Aptahem AB (publ) announces today that the company has received information that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance fo the US patent [...]

Aptahem AB (publ) announce today that the collaboration with the Cardiovascular Research Centre (CVRC) at Örebro University to map the details behind Apta-1’s effects with the support from the [...]

BioStock published an article on 26 May 2021 about Aptahem, which can be read in full below. The most anticipated milestone for sepsis company Aptahem is initiating first-in-human trials with [...]

BioStock published an article on 5 May 2021 about Aptahem, which can be read in full below. Biotechnology company Aptahem, which is developing the preclinical drug candidate Apta-1 for the [...]

BioStock published an article on 24 March 2021 about Aptahem, which can be read in full below. Aptahem is developing the drug candidate Apta-1 as an emergency treatment for sepsis, a [...]

BioStock published an article on 10 March 2021 about Aptahem, which can be read in full below. Aptahem announced yesterday that the company has entered into a non binding Term Sheet (NBTS) with a [...]

Aptahem AB (publ) announce today that the company has signed an NBTS (non binding Term Sheet) with a mid-sized pharmaceutical company with head quarters in Europe. The NBTS relates to license [...]